Home
GSC Biological and Pharmaceutical Sciences
Peer-reviewed Journal | Impact factor 8.1 | ISSN: 2581-3250 | CAS Source Indexed | Crossref DOI

Main navigation

  • Home
    • Journal Information
    • Editorial Board Members
    • Reviewer Panel
    • Abstracting and Indexing
    • Journal Policies
    • Our CrossMark Policy
    • Publication Ethics
    • Issue in Progress
    • Current Issue
    • Past Issues
    • Instructions for Authors
    • Article processing fee
    • Track Manuscript Status
    • Get Publication Certificate
    • Join Editorial Board
    • Join Reviewer Panel
  • Contact us
  • Downloads

Research and review articles are invited for publication in September 2026 - Vol. 36, Issue 3 

🌟 GSC Biological and Pharmaceutical Sciences (GSCBPS) 🌟

Low Publication Charges | Fast Editorial Processing | Crossref DOI Linking | Transparent Peer-Review Process

Publishing quality research in Biological Sciences, Pharmaceutical Sciences, Medicine, Healthcare and Allied Life Sciences.

e-ISSN: 2581-3250 | Impact Factor: 8.1 | Established: 2017 | Charges: USD 35 / INR 2100

📄 Submit Manuscript 👉 Author Guidelines 📚 Published Articles 

Antimicrobial resistance in clinical wound infections: A study on Escherichia coli and Pseudomonas aeruginosa isolates from patients in Imo state, Nigeria

Breadcrumb

  • Home
  • Antimicrobial Resistance In Clinical Wound Infections: A Study On Escherichia Coli and Pseudomonas Aeruginosa Isolates From Patients In Imo State, Nigeria
  • Antimicrobial resistance in clinical wound infections: A study on Escherichia coli and Pseudomonas aeruginosa isolates from patients in Imo state, Nigeria

Chioma S. Mark-Ogu *, Enuma E. Mike-Anosike, and Chinwe I. Chikwendu

Department of Microbiology, Federal University of Technology, Owerri, Nigeria.
Research Article
GSC Biological and Pharmaceutical Sciences, 2025, 33(01), 216-222.
Article DOI: 10.30574/gscbps.2025.33.1.0401
DOI url: https://doi.org/10.30574/gscbps.2025.33.1.0401
Received on 09 September 2025; revised on 19 October 2025; accepted on 22 October 2025
Background: The growing resistance of Escherichia coli and Pseudomonas aeruginosa to antimicrobial treatments poses a major public health concern, particularly in the treatment of hospital-acquired wound infections.
Aim: This study investigated the antimicrobial resistance profile of Escherichia coli and Pseudomonas aeruginosa isolated from patients with wound infections in Imo State, Nigeria.
Study Design: A total of 76 bacterial isolates, comprising Escherichia coli and Pseudomonas aeruginosa, were recovered from patients with clinically infected wounds and subjected to antimicrobial susceptibility testing against a panel of antibiotics representing multiple antibiotic classes, to determine their antimicrobial resistance profiles.
Methodology: Antimicrobial susceptibility testing was performed using the disc diffusion method, as outlined in the Clinical and Laboratory Standards Institute CLSI (2017) guidelines. The isolates were tested against cephalosporins, carbapenems, polymyxins, and quinolones, which include ceftazidime (10μg), ceftriaxone (30μg), cefepime (30μg), imipenem (10μg), meropenem (10μg), colistin (10μg), polymyxin B (30μg), ciprofloxacin (5μg), and levofloxacin (5μg), to determine susceptibility profiles.
Results: Findings revealed a high prevalence of multidrug resistance (MDR) among the gram-negative bacterial isolates, with a substantial proportion of isolates exhibiting resistance to three or more antibiotic classes. Specifically, 43.9% (18) of Pseudomonas aeruginosa and 45.71% (16) of Escherichia coli isolates were identified as MDR.
Notably, a significant number of Escherichia coli and Pseudomonas aeruginosa isolates exhibited resistance to various antibiotic classes, including cephalosporins, carbapenems, polymyxins, and quinolones. However, carbapenems demonstrated remarkable efficacy, with a significant majority of isolates showing susceptibility — 92.68% of Pseudomonas aeruginosa and 90% of Escherichia coli isolates.
Conclusion: The study highlights the urgent need for robust antimicrobial stewardship and infection control practices to preserve the efficacy of available antibiotics in the treatment of clinical wound infections.
Pseudomonas aeruginosa; Escherichia coli; Wound infection; Multidrug resistance; Antimicrobial resistance; Carbapenems
https://gscbps.gsconlinepress.com/sites/default/files/fulltext_pdf/GSCBPS-2025-…

Preview Article PDF

Chioma S. Mark-Ogu, Enuma E. Mike-Anosike and Chinwe I. Chikwendu. Antimicrobial resistance in clinical wound infections: A study on Escherichia coli and Pseudomonas aeruginosa isolates from patients in Imo state, Nigeria. GSC Biological and Pharmaceutical Sciences, 2025, 33(1), 216-222. Article DOI: https://doi.org/10.30574/gscbps.2025.33.1.0401


📝 Copyright, Licensing and Permissions: © Copyright Author(s). This article is published under the 🌐 Creative Commons Attribution 4.0 International License (CC BY 4.0) , which permits unrestricted use, distribution, adaptation, and reproduction in any medium, provided the original author(s) and source are properly credited, a link to the license is provided, and any changes made are indicated.


⚠️ Disclaimer: The statements, opinions, interpretations, and data presented in this publication are solely those of the individual author(s). GSC Biological and Pharmaceutical Sciences (GSCBPS), the editors, reviewers, editorial board, and publisher disclaim responsibility for any errors, omissions, or consequences arising from the use of the information contained in this article.


🏆 Get Publication Certificate 📄 Download Letter of Acceptance 🔗 Verify Crossref DOI 📘 View Issue Cover Page 👨‍🔬 Editorial Board 📑 Table of Contents 

🚀 Publish Your Research in International Peer Reviewed Open Access Journal - GSC Biological and Pharmaceutical Sciences (GSCBPS)

Submit your manuscripts from Biological Sciences, Pharmaceutical Sciences, Medicine, Healthcare, Biotechnology and Allied Life Sciences etc.

🌍 International Journal   |   👨‍🔬 Transparent Peer Review Process   |   🌐 Open Access Publishing   |   🔗 Crossref DOI 
⚡ Fast Editorial Processing   |   💰 Low Publication Charges

📝 Submit Your Manuscript 📘 Author Guidelines 💰 Publication Charges 

✅ No Submission Fee •  📜 Free Publication Certificate • 🌍 Global Visibility

⭐ Popular Pages


  • 🌍 International Journal
  • 🌐 Open Access Journal
  • 👨‍⚖️ Peer-Reviewed Journal
  • 💰 Low APC Journal
  • 🚀 Fast Publication Journal
  • ⚡ Fast-Track Peer-Review
  • 🔗 Crossref DOI Journal
  • 📖 Refereed Journal
  • 📈 High Impact Journal
  • 🧬 International Biology Journal
  • 💊 International Pharmacy Journal
  • 📝 Publish Research Paper

✍️ Author Resources


  • 📝 Publish Research Paper
  • 📖 Author Guidelines
  • 🎯 Aims and Scope
  • 💳 Article Processing Charges
  • 📤 Submit Manuscript
  • 📄 Cover Letter
  • ✍️ Author Declaration Form
  • 📄Track Manuscript Status
  • 📜 Get Publication Certificate
  • 📚 Journal Past Issue Archive
  • 🔎 Journal Indexing

⚖️ Journal Policies


  • ⚖️ Publication Ethics
  • 🛡️ Plagiarism Policy
  • 👨‍🔬 Peer Review Policy
  • 👨‍⚖️ Peer Review Process
  • 📖 Open Access Publishing
  • 📜 Copyright & Licensing
  • 🔗Author Self-Archiving Policy
  • 👥 Authorship Policy
  • 📊 Data Sharing Policy
  • 🤖 AI Usage Policy

Copyright © 2026 GSC Biological and Pharmaceutical Sciences - All rights reserved

Developed & Designed by VS Infosolution